Definitive Healthcare Corp. — Q1 2022 Form 10-Q
Business context and period. The filing covers the three months ended March 31, 2022. Definitive Healthcare provides healthcare commercial intelligence through a SaaS platform; subscription services generated approximately 99% of revenue. The 2022 results reflect the public-company structure after the 2021 IPO reorganization, while 2021 comparative results represent the historical operating company, which limits some period-to-period comparability.
Key financial results
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | $50.1 million | $36.9 million |
| Gross profit / GAAP gross margin | $38.8 million / 77.4% | $27.5 million / 74.5% |
| Operating loss | $11.0 million | $2.2 million |
| Net loss | $13.1 million | $10.5 million |
| Net loss attributable to Definitive Healthcare Corp. | $8.6 million; $0.09 per share | Not presented on a comparable per-share basis |
| Operating cash flow | $13.6 million | $13.5 million |
| Adjusted EBITDA / margin | $14.0 million / 28% | $14.1 million / 38% |
| Adjusted gross margin | 88% | 88% |
Revenue rose 36%, mainly from expansion among existing customers and new customer additions. GAAP operating expenses increased 68% to $49.8 million, led by higher sales and marketing, product development, and general and administrative costs, including hiring and public-company expenses. Consequently, operating loss widened despite revenue growth. Net loss increased 24%; lower interest expense partly offset higher operating costs.
Cash and cash equivalents were $229.8 million at March 31, 2022, down from $387.5 million at year-end. Short-term investments were $109.0 million, and $75.0 million remained available under the revolving facility. Investing cash outflow was $166.9 million, primarily $109.6 million of short-term investment purchases and $56.5 million of cash paid for the Analytical Wizards acquisition. Financing cash outflow was $4.4 million.
Term-loan principal was $271.6 million ($269.1 million net of issuance costs), with $6.9 million classified as current; the $75.0 million revolver was undrawn. The loan matures in September 2026 and includes an approximately $220.0 million balloon payment. The company reported covenant compliance. A $154.7 million tax receivable agreement liability was recorded; the company generally owes participating former owners 85% of realized or deemed tax benefits.
Changes, outlook, and risks
- Acquisition: The company acquired the remaining 65% of Analytical Wizards on February 18 for total consideration of approximately $99.6 million, including the earlier investment and estimated contingent consideration. Preliminary purchase accounting recorded $62.1 million of goodwill and $46.0 million of intangible assets; allocation remains subject to change. Post-acquisition results were not material in the quarter.
- Retention and contracted revenue: At March 31, current remaining performance obligations were $164.5 million and total obligations were $261.0 million, versus $155.1 million and $250.5 million, respectively, at year-end. Reported 2021 NDR was 120% for enterprise customers and 111% for customers above $17,500 ARR; the filing does not provide a new Q1 NDR.
- Management outlook: No specific revenue or earnings guidance is provided. Management expects liquidity from operating cash flows, available credit, cash, and short-term investments to meet needs for at least 12 months. It expects sales and marketing and product development investment to continue; public-company costs are expected to raise G&A expense in 2022. Management anticipates lower 2022 interest expense than prior periods following debt repayment and refinancing, while noting swaps could increase interest expense in the short term.
- Hedging and other items: Two cash-flow interest-rate swaps were entered into in March, each with a $67.9 million notional amount, maturing in March 2025. The company expects to reclassify approximately $0.3 million of net pretax gains from accumulated other comprehensive income to interest expense over the next 12 months. It adopted lease accounting on January 1, recognizing $12.7 million of operating lease right-of-use assets and $14.0 million of lease liabilities at adoption.
- Risks and contingencies: The term loan has variable-rate exposure; absent swaps, a 1 percentage-point rate change would have affected quarterly interest expense by approximately $0.7 million. Management cited uncertainty around economic conditions and the longer-term COVID-19 impact, and warned that inflationary cost increases may not be fully offset by pricing. The company has ordinary-course legal matters but does not expect their resolution to materially adversely affect its financial position, results, or cash flows. No material change in risk factors from the 2021 Form 10-K was reported.
Important facts for investors to verify
- Whether revenue growth and customer expansion continue, and how current NDR compares with the disclosed 2021 rates.
- Whether operating expense growth moderates and adjusted EBITDA margin stabilizes; adjusted measures exclude specified costs and are not GAAP substitutes.
- Cash generation and liquidity after acquisition spending, investment purchases, debt service, and any further acquisitions.
- Final purchase-price allocation and performance of Analytical Wizards, including contingent consideration of up to $5.0 million.
- Variable-rate debt exposure, swap effectiveness, the 2026 maturity and balloon payment, and potential future tax receivable agreement payments.